目前使用双特异性抗体治疗多发性骨髓瘤
Holly Lee1, Paola Neri1, Nizar J Bahlis1
1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Hematology. American Society of Hematology. Education Program
|December 9, 2023
概括
双特异性T细胞参与剂 (BsAb) 在多发性骨髓瘤 (MM) 中表现有前途. 了解抵抗机制,包括瘤内在因素和免疫逃避,对于优化MM患者的BsAb治疗至关重要.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 向免疫疗法,特别是双特异性T细胞参与剂 (BsAb),已经改变了血液性恶性瘤的结果.
- 在多发性骨髓瘤 (MM) 中,针对BCMA,GPRC5D和FcRL5的BsAb在耐火患者中表现出显著的活性.
研究的目的:
- 阐明多发性骨髓瘤中对双特异性T细胞吸引治疗的耐药性机制.
- 为开发优化的BsAb策略和MM的组合疗法提供信息.
主要方法:
- 审查报告的瘤内在耐药性因素,包括抗原损失和增加可溶性点.
- 分析免疫介导的抵抗机制,重点关注T细胞适应性和免疫耐受性.
主要成果:
- 瘤内在耐药性包括目标基因缺失/突变,可溶性抗原释放,高瘤负担和外骨髓性疾病.
- 免疫介导的抵抗与T细胞耗尽和免疫抑制瘤微环境有关.
结论:
- 了解耐药机制是克服BsAb在MM中的治疗局限性的关键.
- 优化的BsAb设计,测序和与其他药物的组合对于改善MM患者的治疗结果至关重要.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
142
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142


